

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**CanSino Biologics Inc.**  
**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6185)**

**POLL RESULTS OF  
THE 2021 THIRD EXTRAORDINARY GENERAL MEETING**

**POLL RESULTS OF THE EGM**

The Board hereby announces the poll results in respect of the ordinary resolutions proposed at the EGM on Monday, October 11, 2021. All ordinary resolutions were duly passed.

**APPOINTMENT OF EXECUTIVE DIRECTOR**

At the EGM, Ms. Jing WANG (“**Ms. Wang**”) was appointed as an executive Director of the second session of the Board.

References are made to the notice (the “**Notice**”) and the circular (the “**Circular**”) of the 2021 third extraordinary general meeting (the “**EGM**”) of CanSino Biologics Inc. (the “**Company**”) dated September 23, 2021, and the announcement of the Company dated September 10, 2021, in relation to, among other things, the proposed appointment of Director. Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The Company announces that at its EGM held on Monday, October 11, 2021, all ordinary resolutions proposed were duly passed. The EGM was convened by the board (the “**Board**”) of directors (the “**Directors**”) of the Company. Further details of the ordinary resolutions are set out in the Notice and the Circular.

**ATTENDANCE AT THE EGM**

The Board is pleased to announce that the EGM was held at 2:00 p.m. on Monday, October 11, 2021 at No. 2 Ballroom, 2nd Floor, Hyatt Regency Tianjin East, No. 126 Weiguo Road, Hedong District, Tianjin, the People's Republic of China.

The attendance of the EGM is as follows:

<b>Class of Shares</b>	<b>Number of Shares in issue (and entitling holders to attend and vote for or against any resolution)</b>	<b>Number of Shares present (in person or by proxy)</b>	<b>Approximate %</b>
H Shares	132,670,900	70,839,486	53.3949
A Shares	114,778,999	60,581,798	52.7813
<b>Total</b>	<b>247,449,899</b>	<b>131,421,284</b>	<b>53.1103</b>

To the best knowledge, information and belief of the Company: (1) there were no Shares entitling the holder to attend and abstain from voting in favor of the resolutions proposed at the EGM as set out in Rule 13.40 of the Listing Rules; (2) no Shareholder was required under the Listing Rules to abstain from voting on the resolutions proposed at the EGM; and (3) no party has stated any intention in the Circular to vote against or to abstain from voting on the resolutions proposed at the EGM.

## **POLL RESULTS OF THE EGM**

The poll results of the EGM were as follows:

<b>Ordinary Resolutions<sup>(1)</sup></b>		<b>For<sup>(3)</sup></b>	<b>Against<sup>(3)</sup></b>	<b>Abstain<sup>(3)</sup></b>	<b>Passed by Shareholders<sup>(2)</sup></b>
1.	To consider and approve the proposed appointment of Ms. Jing WANG as an executive Director.	130,667,225 (99.8029%)	258,108 (0.1971%)	0 (0.0000%)	Yes
2.	To consider and approve the proposed use of part of the Over-raised Proceeds to permanently supplement working capital.	131,365,927 (99.9579%)	55,357 (0.0421%)	0 (0.0000%)	Yes

*Notes:*

- (1) Please refer to the Notice and Circular for details of the ordinary resolutions.
- (2) An ordinary resolution is passed by more than half of the votes casted in favor of it.
- (3) All percentages were rounded to four decimal places. The percentage figures included in this table have been subject to rounding adjustments.

## **APPOINTMENT OF EXECUTIVE DIRECTOR**

At the EGM, Ms. Wang was appointed as an executive Director of the second session of the Board. The appointment of Ms. Wang shall come into effect immediately after conclusion of the EGM and until the expiry of the term of the second session of the Board. For details of Ms. Wang's biography and the determination of her remuneration, please refer to the announcement of the Company dated September 10, 2021 and the Circular. As of the date of this announcement, there was no change in such information.

## **SCRUTINEERS**

The H share registrar of the Company, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the EGM. Two representatives of the Shareholders, one lawyer of Tian Yuan Law Firm, and one supervisor of the Company participated in the scrutiny of the poll results.

By order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, October 11, 2021

*As of the date of this announcement, the Board comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive Directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.*